Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04879368 · ClinicalTrials.gov registry record · Phase 3
RegoNivo vs Standard of Care Chemotherapy in AGOC
A Phase 3 study of Gastro-Oesophageal Cancer, sponsored by Australasian Gastro-Intestinal Trials Group.
- Active
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT04879368 is a Phase 3 study of Gastro-Oesophageal Cancer that is active but no longer recruiting, run by Australasian Gastro-Intestinal Trials Group. The registered enrollment target is 450 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT04879368, a Phase 3 study of Gastro-Oesophageal Cancer, is active but no longer recruiting, sponsored by Australasian Gastro-Intestinal Trials Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG Regorafenib
- BIOLOGICAL Nivolumab
- DRUG Irinotecan
Study Locations (20)
New South Wales
- Coffs Harbour Health Campus - Coffs Harbour
- Concord Repatriation General Hospital - Concord
- St Vincent's Public Hospital - Darlinghurst
- Border Medical Oncology Research Unit - East Albury
- Gosford Hospital - Gosford
- St George Hospital - Kogarah
- Newcastle Private Hospital - New Lambton Heights
- Port Macquarie Base Hospital - Port Macquarie
- Prince of Wales Hospital - Randwick
- Royal North Shore Private Hospital - Sydney
- The Tweed Hospital - Tweed Heads
- Ballarat Oncology and Haematology Services - Wendouree
- Westmead Hospital - Westmead
Arizona
- Mayo Clinic Arizona - Scottsdale
California
- USC Norris - Los Angeles
Iowa
- Siouxland Regional Cancer Center - Sioux City
Kentucky
- St Elizabeth Healthcare - Edgewood
South Dakota
- Monument Health Rapid City Hospital - Rapid City
Washington
- Fred Hutchinson Cancer Research Centre - South Lake Union Clinic - Seattle
Northern Territory
- Royal Darwin Hospital - Tiwi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04879368
The ClinicalTrials.gov registry entry for NCT04879368 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Australasian Gastro-Intestinal Trials Group, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastro-Oesophageal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.
NCT04879368 reports 20 study locations spanning 8 distinct geographic areas - top geographies include New South Wales, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT04879368 about?
NCT04879368 is a clinical study titled "RegoNivo vs Standard of Care Chemotherapy in AGOC". To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.
What is the current status of trial NCT04879368?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2021-06-01. Estimated completion is 2026-06-01.
What conditions does trial NCT04879368 study?
This clinical trial studies the following conditions: Gastro-Oesophageal Cancer.
What interventions are being tested in trial NCT04879368?
The interventions under investigation include: Docetaxel (DRUG), Paclitaxel (DRUG), Regorafenib (DRUG), Nivolumab (BIOLOGICAL), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT04879368?
This trial is sponsored by Australasian Gastro-Intestinal Trials Group, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04879368 being conducted?
This trial has 20 study locations across Arizona, California, Iowa, Kentucky, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.